Binding characteristics of naftopidil and α1-adrenoceptor antagonists to prostatic α-adrenoceptors in benign prostatic hypertrophy
References (23)
- et al.
J. Urol.
(1985) - et al.
J. Urol.
(1983) - et al.
J. Urol.
(1984) - et al.
Biochem. Biophys. Res. Commun.
(1979) - et al.
J. Urol.
(1986) - et al.
Life Sci.
(1983) - et al.
J. Biol. Chem.
(1951) - et al.
J. Urol.
(1985) - et al.
J. Urol.
(1987) - et al.
Br. J. Urol.
(1975)
Invest. Urol.
(1980)
Cited by (31)
Solubility of naftopidil in pure and mixed solvents at 273.15–313.15 K and its correlation with the Jouyban-Acree and CNIBS/R-K models
2020, Journal of Chemical ThermodynamicsCitation Excerpt :NO. 57149-07-2, its chemical structure was presented in Fig. 1) belongs to phenylpiperazine derivatives and is being marketed under the brand name Flivas®. Naftopidil is a specific subtype of selective α1-adrenoceptor blocker frequently used to treat benign prostatic hyperplasia with fewer side effects [1–7]. Moreover, it also elicits growth-inhibitory effects on androgen-sensitive and androgen-insensitive human prostatic cancer cell lines [8,9].
The use of α-adrenoceptor antagonists in the phamacological management of benign prostatic hypertrophy: An overview
1996, Pharmacological ResearchCharacterization of α<inf>1</inf>-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man
1993, European Journal of Pharmacology
Copyright © 1991 Published by Elsevier Inc.